An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 212479
Company: SHORLA

Products on NDA 212479

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
JYLAMVO	METHOTREXATE	2MG/ML	SOLUTION;ORAL	Prescription	None	Yes	Yes
JYLAMVO	METHOTREXATE	2MG/ML	SOLUTION;ORAL	Prescription	None	No	No
JYLAMVO	METHOTREXATE	2MG/ML	SOLUTION;ORAL	Prescription	None	No	No
JYLAMVO	METHOTREXATE	2MG/ML	SOLUTION;ORAL	Prescription	None	No	No

Approval Date(s) and History, Letters, Labels, Reviews for NDA 212479

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
11/29/2022	ORIG-4	Approval	Efficacy	STANDARD	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212479s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/212479Orig1s000; Orig2s000; Orig3s000; Orig4s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/212479Orig1,Orig2,Orig3,Orig4s000TOC.cfm
11/29/2022	ORIG-3	Approval	Efficacy	STANDARD	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212479s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/212479Orig1s000; Orig2s000; Orig3s000; Orig4s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/212479Orig1,Orig2,Orig3,Orig4s000TOC.cfm
11/29/2022	ORIG-2	Approval	Efficacy	STANDARD	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212479s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/212479Orig1s000; Orig2s000; Orig3s000; Orig4s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/212479Orig1,Orig2,Orig3,Orig4s000TOC.cfm
11/29/2022	ORIG-1	Approval	Type 5 - New Formulation or New Manufacturer	STANDARD	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212479s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/212479Orig1s000; Orig2s000; Orig3s000; Orig4s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/212479Orig1,Orig2,Orig3,Orig4s000TOC.cfm

Labels for NDA 212479

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
11/29/2022	ORIG-4	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212479s000lbl.pdf
11/29/2022	ORIG-3	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212479s000lbl.pdf
11/29/2022	ORIG-2	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212479s000lbl.pdf
11/29/2022	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212479s000lbl.pdf

Top